Fexuprazan for stomach protection during blood thinners
Treatments studied
Part of Digestive system, Heart & circulation clinical trials.
This trial tests whether fexuprazan can help prevent stomach bleeding in people with atrial fibrillation who take blood thinners like apixaban or rivaroxaban. If you are at higher risk for stomach bleeding, this study may offer extra protection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of irregular heartbeat called atrial fibrillation that is not caused by a heart valve problem
- You take or are about to start taking a non-vitamin K oral anticoagulant (blood thinner) at the standard dose
- You have at least one factor that increases your risk of stomach bleeding, such as being 75 or older, having chronic kidney disease, taking aspirin or other antiplatelet drugs, using NSAIDs or steroids regularly, having had a stomach ulcer or stomach bleeding before, or a HAS-BLED score of 3 or higher
- You do not have active stomach bleeding right now
- You do not need long-term acid-blocking medication that cannot be stopped
- You do not have severe liver disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
This study tests the safety of a new blood thinner for people with atrial fibrillation (AFib) who need long-term stroke prevention. If you qualify, the study will compare this medication to standard anticoagulation therapy.
This trial tests a new medication to prevent strokes and blood clots in people with atrial fibrillation (an irregular heartbeat) who cannot safely take standard blood thinners. The drug works by blocking a different clotting factor, which may lower bleeding risks.
This study tests a new blood thinner to prevent strokes and blood clots in people with atrial fibrillation (a common heart rhythm problem). You may qualify if you have atrial fibrillation and at least one risk factor for stroke, or if you've never taken a blood thinner before.
This trial tests whether fexuprazan can prevent upper gastrointestinal bleeding in people at high risk who need two antiplatelet drugs for at least 6 months after a heart stent. If you are on dual antiplatelet therapy after a stent and have risk factors like older age, low weight, or history of ulcers, this study may help protect your stomach.
This study tests whether a medication called fexuprazan can protect your stomach from ulcers while you take NSAIDs (common pain relievers like ibuprofen) for ongoing joint or muscle problems. The trial checks if it's safe and works better than standard care.
Hear when a new Upper Gastrointestinal Bleeding (UGIB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.